Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06262815

The Utility of Treatment With Nasogastric Tube Placement for Small Bowel Obstruction

Small bowel obstruction (SBO) occurs when the normal movements of the small bowel is obstructed, most commonly due to adhesion related to previous abdominal surgery. This may cause strangulation of the small bowel with reduced blood flow which is a surgical emergency requiring prompt treatment in the operating room. If there are no signs of strangulation or ischemia of the bowel at the time of diagnosis, international guidelines recommend initial treatment with intravenous fluids and nasogastric tube placement. However, there is emerging debate regarding non-selective treatment with nasogastric tube placement in patients with SBO. This management started around 1930 as a means to reduce pain in patients with SBO, in conjunction with other additions to management, like intravenous fluids. However the effect and utility of routine nasogastric tube placement have not been prospectively evaluated. There are a total of three retrospective observational studies in the past decade with a total of 759 patients where 292 (36%) were managed without a nasogastric tube. There was no difference in the rates of conservative treatment failure (requiring surgery), complications (vomiting, pneumonia) or mortality between patients receiving a nasogastric tube and those who didn't. However, the retrospective design of these studies limits their validity. Furthermore, nasogastric tube placement has been shown to be one of the more painful interventions patients may experience in-hospital. This calls into question the patient benefit of routine nasogastric tube placement in patients with SBO and further studies are needed to discern the utility of this intervention.

Definitive treatment for SBO is surgical adhesiolysis but there is debate regarding the timing of surgery, particularly in older adults. A large proportion of patients may be managed conservatively with oral contrast and repeated radiological evaluation and the obstruction will resolve in many patients within 24 to 48 hours. This timeframe is dependent on factors related to the disease itself as well as patient related factors like previous surgery and comorbidities. Older patients are at high risk for complications but current available data is insufficient to inform practice in this population. Frailty, a state of increased vulnerability and susceptibility to adverse events, has been shown to be an independent prognosticator in older adults in the Emergency Department(ED) and suggested as a potential measure to risk stratify older adults with SBO. However to the authors knowledge there is no available data on frailty in older adults with SBO and only one prospective observational trial looking at older adults with SBO. Despite SBO being one of the most common surgical emergencies in older adults.

To investigate the potential benefit of nasogastric tube placement in patients with SBO and the ability of frailty to prognosticate outcomes in older adults better evidence is needed.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

Akutmottagningen US Östergötland, Linköping, Östergötland County, Sweden

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosed small bowel obstruction
  • Age 18 or older

Exclusion criteria

  • Abdominal surgery within 7 days
  • Not able to give informed consent

Treatment and study plan

Nasogastric tube placement

Procedure

Conventional nasogastric tube placement done for decompression of small bowel obstruction

Clinical Frailty Scale

Diagnostic Test

The scale described by Rockwood et al. categorizing patients >65 years of age on a 9 item scale depending on the frailty.

Primary outcomes

  1. Pain at Emergency Department discharge

    Time frame: at Emergency Department Discharge, assessed up to 48 hours

    self-reported Pain on a Numeric Rating Scale from 0 to 10 were higher is worse

Secondary outcomes

  1. Nausea at Emergency Department discharge

    Time frame: at Emergency Department discharge, assessed up to 48 hours

    Nausea as self-reported by patients on a numeric rating scale from 0 to 10 were higher is worse

  2. Hospital Length of Stay

    Time frame: Up to 90 days from inclusion

    Duration of days spent in the hospital by patients with Small Bowel obstruction admitted from the Emergency Department

  3. Mortality

    Time frame: up to 90 days from inclusion

    Mortality of any cause

  4. Admission for Small bowel obstruction

    Time frame: up to 365 days from inclusion in the study

    Any admission to a hospital in Sweden with a primary discharge diagnosis of small bowel obstruction

  5. Emergency Surgery

    Time frame: up to 30 days from inclusion

    Any emergency operation

  6. Emergency Department Length of Stay

    Time frame: up to 7 days from inclusion

    Length of stay, defined as the time from registration in the Emergency Department to discharge from the Emergency Department at the visit of inclusion.

Sponsors and collaborators

Lead sponsor

Daniel Wilhelms

Other

Collaborators

  • Linkoeping University

Registry information

Official study title

The Utility of Treatment With Nasogastric Tube Placement for Small Bowel Obstruction in Adult Patients in the Emergency Department; an Observational Multicenter Study

Acronym: NGTUBE-OBS

Important dates

Study start
2024
Primary completion
2025
Study completion
2026
First posted
Feb 16, 2024
Registry last updated
Apr 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.